Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
5 Results Found
Mark Cuban Lays Out More Details about How He’s Disrupting Drug Pricing
Learn how Mark Cuban is disrupting drug pricing and making waves in the pharmaceutical industry. Find out more about his Cost Plus Drugs company and its collaborations with payers and pharmacists.
3 Ways GLP-1 Drugs Could Impact Your Hospital’s Future
Glucagon-like peptide-1 agonist drugs have been surging in popularity, and manufacturers are scurrying to keep up with demand. Overall, the GLP-1 market is expected to experience annual growth exceeding 20% and will hit $133 billion worldwide by 2030, according to a MarketWatch report from February.
Cost-Plus Drug Pricing Models Gain Momentum, but Will They Last?
CVS Health plans to launch its CVS CostVantage and CVS Caremark TrueCost programs in 2025. CostVantage will define the drug cost and related reimbursement with contracted PBMs and payers, CVS noted in a statement.
Will Startup PBMs Drive Drug Price Transparency?
The Purchaser Business Group on Health (PBGH), a coalition of about 40 large private and public employers including Walmart, Disney, Costco and Microsoft, recently launched EmsanaRx, a nonprofit PBM. Meanwhile, billionaire Mark Cuban’s Cost Plus Drug Company is another PBM that launched recently.
How Rx Drug Pricing Is Ripe for Disruption
A recent report in MobiHealth News explores how well-funded, established startups and fledgling companies alike are finding ways to cut the costs of prescription medications. Their services are targeted to the more than 27 million consumers who are uninsured or underinsured — including the 43 percent of Americans younger than 65 who were on high-deductible plans in 2017 — according to Centers for Disease Control and Prevention data.